Results 21 to 30 of about 72,405 (280)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients

open access: yesInflammatory Intestinal Diseases, 2021
Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter   +2 more
doaj   +1 more source

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

open access: yesBMJ Open Gastroenterology, 2021
Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein   +6 more
doaj   +1 more source

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

open access: yesJournal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor   +3 more
doaj   +1 more source

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis [PDF]

open access: yes, 2013
Technology: Infliximab and comparator biological such as adalimumab, etanercept, golimumab. Conditions: Ankylosing spondylitis (AS) Issue: Infliximab is registered to be used in patients with AS.
Péntek, Márta
core   +1 more source

Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy.

open access: yesPLoS Biology, 2019
During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu   +13 more
doaj   +1 more source

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

open access: yesمجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil   +2 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

open access: yesRespiratory Research, 2022
Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat   +9 more
doaj   +1 more source

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

open access: yesArthritis Research & Therapy, 2019
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis   +3 more
doaj   +1 more source

Specialized enteral nutrition therapy in Crohn’s disease patients on maintenance infliximab therapy: a meta-analysis

open access: yesTherapeutic Advances in Gastroenterology, 2015
Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy